Larsucosterol clinical trials
Also written DUR-928.
How each study uses larsucosterol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the larsucosterol studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Durect (5) · Craig James McClain (1) · Bausch Health Americas, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test larsucosterol, phase 3 first.
- Nov 2027Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)Phase 3 · Bausch Health Americas, Inc.
Studies
Open first, then newest update. How each study uses larsucosterol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)RecruitingPhase 3Bausch Health Americas, Inc.NCT07428538Written as Larsucosterol
- A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic HepatitisCompletedPhase 2DurectNCT03432260Written as DUR-928 30 mg
- A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentCompletedPhase 2DurectNCT04563026Written as DUR-928 30 mg
- DUR-928 in Patients With Alcoholic HepatitisCompletedPhase 2Craig James McClainNCT03917407Written as DUR-928 (Moderate AH)
- A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)TerminatedPhase 2DurectNCT03394781Written as DUR-928
- Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisCompletedPhase 2DurectNCT03837743Written as DUR-928 Topical Solution
- DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney InjuryTerminatedPhase 2DurectNCT04447404Written as DUR-928
Codes
What other systems call larsucosterol · ClinicalTrials.gg INT005386
- UNII (FDA) UGX2V7MGMZLARSUCOSTEROLOne source FDA
- NCI Thesaurus C179097LarsucosterolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | UGX2V7MGMZ | LARSUCOSTEROL | One source FDA |
| NCI Thesaurus | C179097 | Larsucosterol | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.